APA Style
Ranxha, E. , Ranxha, E. Kënga, D. , Kënga, D. Basha, E. , Basha, E. Mali, E. , & Mali, E. (2024). Neuroprotection: at what cost, at what time, at what price?.
Current Research in Public Health, 4(1), 30-34.
https://doi.org/10.31586/wjcmr.2024.1082
ACS Style
Ranxha, E. ; Ranxha, E. Kënga, D. ; Kënga, D. Basha, E. ; Basha, E. Mali, E. ; Mali, E. Neuroprotection: at what cost, at what time, at what price?.
Current Research in Public Health 2024 4(1), 30-34.
https://doi.org/10.31586/wjcmr.2024.1082
Chicago/Turabian Style
Ranxha, Eris, Eris Ranxha. Drilona Kënga, Drilona Kënga. Entela Basha, Entela Basha. Egi Mali, and Egi Mali. 2024. "Neuroprotection: at what cost, at what time, at what price?".
Current Research in Public Health 4, no. 1: 30-34.
https://doi.org/10.31586/wjcmr.2024.1082
AMA Style
Ranxha E, Ranxha EKënga D, Kënga DBasha E, Basha EMali E, Mali E. Neuroprotection: at what cost, at what time, at what price?.
Current Research in Public Health. 2024; 4(1):30-34.
https://doi.org/10.31586/wjcmr.2024.1082
@Article{crph1082,
AUTHOR = {Ranxha, Eris and Kënga, Drilona and Basha, Entela and Mali, Egi and Vyshka, Gentian},
TITLE = {Neuroprotection: at what cost, at what time, at what price?},
JOURNAL = {Current Research in Public Health},
VOLUME = {4},
YEAR = {2024},
NUMBER = {1},
PAGES = {30-34},
URL = {https://www.scipublications.com/journal/index.php/WJCMR/article/view/1082},
ISSN = {2831-5162},
DOI = {10.31586/wjcmr.2024.1082},
ABSTRACT = {Stroke and its disability have deserved the notoriety of a severe and potentially lethal condition, whose treatment is still challenging. The widely craved result of saving as much as possible from the neural tissue and eventually reviving what is thought to be in the ischemic penumbra – if not already dead and gone – is the outcome every clinician is dreaming of. There are several reviews on the issue, which have discussed several options of achieving neuroprotection in acute ischemic stroke. Of course, reviews are not and do not pretend to be exhaustive; new drugs enter repeatedly in the scene. We would limit our comments on some of the pharmacological agents, that although seem to be worldwide available, are still looking for obtaining the citizenship in the therapeutic armamentarium of acute ischemic stroke.},
}
%0 Journal Article
%A Ranxha, Eris
%A Kënga, Drilona
%A Basha, Entela
%A Mali, Egi
%A Vyshka, Gentian
%D 2024
%J Current Research in Public Health
%@ 2831-5162
%V 4
%N 1
%P 30-34
%T Neuroprotection: at what cost, at what time, at what price?
%M doi:10.31586/wjcmr.2024.1082
%U https://www.scipublications.com/journal/index.php/WJCMR/article/view/1082
TY - JOUR
AU - Ranxha, Eris
AU - Kënga, Drilona
AU - Basha, Entela
AU - Mali, Egi
AU - Vyshka, Gentian
TI - Neuroprotection: at what cost, at what time, at what price?
T2 - Current Research in Public Health
PY - 2024
VL - 4
IS - 1
SN - 2831-5162
SP - 30
EP - 34
UR - https://www.scipublications.com/journal/index.php/WJCMR/article/view/1082
AB - Stroke and its disability have deserved the notoriety of a severe and potentially lethal condition, whose treatment is still challenging. The widely craved result of saving as much as possible from the neural tissue and eventually reviving what is thought to be in the ischemic penumbra – if not already dead and gone – is the outcome every clinician is dreaming of. There are several reviews on the issue, which have discussed several options of achieving neuroprotection in acute ischemic stroke. Of course, reviews are not and do not pretend to be exhaustive; new drugs enter repeatedly in the scene. We would limit our comments on some of the pharmacological agents, that although seem to be worldwide available, are still looking for obtaining the citizenship in the therapeutic armamentarium of acute ischemic stroke.
DO - Neuroprotection: at what cost, at what time, at what price?
TI - 10.31586/wjcmr.2024.1082
ER -
